Gilead Sciences Inc
GILDView Detailed Chart
107.250USD
-5.140-4.57%
Close 04/04, 16:00（ET）Quotes delayed by 15 min
133.63BMarket Cap
278.40P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.57%
5 Days
-4.06%
1 Month
-7.09%
6 Months
+26.78%
Year to Date
+16.10%
1 Year
+54.13%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
30
analysts
BUY
Current Rating
110.546
Target Price
3.07%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
150
Total
5
Median
7
Average
Company name
Ratings
Analysts
Gilead Sciences Inc
GILD
30
Biogen Inc
BIIB
37
Amgen Inc
AMGN
33
Alnylam Pharmaceuticals Inc
ALNY
33
BioMarin Pharmaceutical Inc
BMRN
29
Eli Lilly and Co
LLY
29
1
2
3
...
30
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.926
Neutral
RSI(14)
45.307
Neutral
STOCH(KDJ)(9,3,3)
45.153
Sell
ATR(14)
2.721
High Vlolatility
CCI(14)
-13.381
Neutral
Williams %R
74.527
Sell
TRIX(12,20)
0.120
Sell
StochRSI(14)
0.000
Sell
Moving Average
Indicators
Value
Direction
MA5
110.964
Sell
MA10
110.153
Sell
MA20
110.672
Sell
MA50
105.189
Buy
MA100
98.536
Buy
MA200
88.106
Buy
News
More news coming soon, stay tuned...
Company
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.
Company codeGILD
CompanyGilead Sciences Inc
CEOMr. Daniel P O'Day
Websitehttps://www.gilead.com/
